7vqp

Vitamin D receptor complexed with a lithocholic acid derivativeVitamin D receptor complexed with a lithocholic acid derivative

Structural highlights

7vqp is a 2 chain structure with sequence from Homo sapiens and Rattus norvegicus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	X-ray diffraction, Resolution 1.94Å
Ligands:
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

VDR_RAT Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Regulates transcription of hormone sensitive genes via its association with the WINAC complex, a chromatin-remodeling complex. Recruited to promoters via its interaction with the WINAC complex subunit BAZ1B/WSTF, which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.^[1]

Publication Abstract from PubMed

1alpha,25-Dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3), 1] is an active form of vitamin D(3) and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR). Lithocholic acid (LCA, 2) was identified as a second endogenous agonist of VDR, though its potency is very low. However, the lithocholic acid derivative 3 (Dcha-20) is a more potent agonist than 1alpha,25(OH)(2)D(3), (1), and its carboxyl group has similar interactions to the 1,3-dihydroxyl groups of 1 with amino acid residues in the VDR ligand-binding pocket. Here, we designed and synthesized amide derivatives of 3 in order to clarify the role of the carboxyl group. The synthesized amide derivatives showed HL-60 cell differentiation-inducing activity with potency that depended upon the substituent on the amide nitrogen atom. Among them, the N-cyanoamide 6 is more active than either 1 or 3.

Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists.,Yoshihara A, Kawasaki H, Masuno H, Takada K, Numoto N, Ito N, Hirata N, Kanda Y, Ishizawa M, Makishima M, Kagechika H, Tanatani A Biomolecules. 2022 Jan 14;12(1):130. doi: 10.3390/biom12010130. PMID:35053278^[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Vanhooke JL, Tadi BP, Benning MM, Plum LA, DeLuca HF. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch Biochem Biophys. 2007 Apr 15;460(2):161-5. Epub 2006 Dec 12. PMID:17227670 doi:10.1016/j.abb.2006.11.029
↑ Yoshihara A, Kawasaki H, Masuno H, Takada K, Numoto N, Ito N, Hirata N, Kanda Y, Ishizawa M, Makishima M, Kagechika H, Tanatani A. Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists. Biomolecules. 2022 Jan 14;12(1):130. PMID:35053278 doi:10.3390/biom12010130

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

[1] Vanhooke JL, Tadi BP, Benning MM, Plum LA, DeLuca HF. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch Biochem Biophys. 2007 Apr 15;460(2):161-5. Epub 2006 Dec 12. PMID:17227670 doi:10.1016/j.abb.2006.11.029

[2] Yoshihara A, Kawasaki H, Masuno H, Takada K, Numoto N, Ito N, Hirata N, Kanda Y, Ishizawa M, Makishima M, Kagechika H, Tanatani A. Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists. Biomolecules. 2022 Jan 14;12(1):130. PMID:35053278 doi:10.3390/biom12010130

[1]

[2]